Pieris Pharmaceuticals 将来の成長
Future 基準チェック /06
現在、 Pieris Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。
主要情報
n/a
収益成長率
n/a
EPS成長率
| Biotechs 収益成長 | 28.4% |
| 収益成長率 | n/a |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | None |
| 最終更新日 | n/a |
今後の成長に関する最新情報
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pieris Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。
シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。
業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 9/30/2024 | 1 | -16 | -28 | -28 | N/A |
| 6/30/2024 | 21 | -24 | -38 | -38 | N/A |
| 3/31/2024 | 41 | -16 | -50 | -50 | N/A |
| 12/31/2023 | 43 | -25 | -54 | -54 | N/A |
| 9/30/2023 | 47 | -28 | -47 | -47 | N/A |
| 6/30/2023 | 33 | -27 | -46 | -46 | N/A |
| 3/31/2023 | 17 | -41 | -49 | -48 | N/A |
| 12/31/2022 | 26 | -33 | -61 | -60 | N/A |
| 9/30/2022 | 28 | -35 | -59 | -58 | N/A |
| 6/30/2022 | 27 | -42 | -65 | -64 | N/A |
| 3/31/2022 | 27 | -47 | -19 | -18 | N/A |
| 12/31/2021 | 31 | -46 | -9 | -8 | N/A |
| 9/30/2021 | 25 | -51 | -11 | -10 | N/A |
| 6/30/2021 | 24 | -48 | -3 | -3 | N/A |
| 3/31/2021 | 32 | -38 | -44 | -43 | N/A |
| 12/31/2020 | 29 | -37 | -49 | -46 | N/A |
| 9/30/2020 | 45 | -26 | -50 | -46 | N/A |
| 6/30/2020 | 57 | -15 | -56 | -52 | N/A |
| 3/31/2020 | 51 | -22 | -57 | -52 | N/A |
| 12/31/2019 | 46 | -28 | -55 | -52 | N/A |
| 9/30/2019 | 34 | -36 | -49 | -48 | N/A |
| 6/30/2019 | 27 | -40 | -51 | -49 | N/A |
| 3/31/2019 | 33 | -28 | -49 | -48 | N/A |
| 12/31/2018 | 29 | -27 | -3 | -1 | N/A |
| 9/30/2018 | 42 | -8 | 1 | 3 | N/A |
| 6/30/2018 | 38 | -8 | N/A | 53 | N/A |
| 3/31/2018 | 28 | -18 | N/A | 55 | N/A |
| 12/31/2017 | 25 | -18 | N/A | 50 | N/A |
| 9/30/2017 | 10 | -32 | N/A | 48 | N/A |
| 6/30/2017 | 7 | -31 | N/A | 9 | N/A |
| 3/31/2017 | 6 | -27 | N/A | 9 | N/A |
| 12/31/2016 | 6 | -23 | N/A | -14 | N/A |
| 9/30/2016 | 5 | -19 | N/A | -10 | N/A |
| 6/30/2016 | 5 | -17 | N/A | -10 | N/A |
| 3/31/2016 | 4 | -15 | N/A | -7 | N/A |
| 12/31/2015 | 3 | -14 | N/A | -13 | N/A |
| 9/30/2015 | 4 | -15 | N/A | -10 | N/A |
| 6/30/2015 | 4 | -13 | N/A | -8 | N/A |
| 3/31/2015 | 4 | -13 | N/A | -8 | N/A |
| 12/31/2014 | 5 | -10 | N/A | -5 | N/A |
| 9/30/2014 | 6 | -5 | N/A | -6 | N/A |
| 12/31/2013 | 12 | 0 | N/A | -3 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: PIRSの予測収益成長が 貯蓄率 ( 2.6% ) を上回っているかどうかを判断するにはデータが不十分です。
収益対市場: PIRSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です
高成長収益: PIRSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。
収益対市場: PIRSの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。
高い収益成長: PIRSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: PIRSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です